Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

535 Barnhill Drive, Indianapolis, IN 46202

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center, located in Indianapolis, is Indiana’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and one of only 51 in the nation. The comprehensive designation recognizes the center’s excellence in basic, clinical, and population research, outstanding educational activities, and effective community outreach program across the state.

The center’s nearly 250 scientists conduct research in four programs. The goals of those programs range from understanding the molecular changes that cause cancer to developing targeted therapies to prevent and treat cancer.

Home to the cure of testicular cancer, the IU Simon Comprehensive Cancer Center has benefitted countless patients around the globe by altering or defining treatment standards for:

  • breast cancer
  • gastrointestinal cancer, including pancreatic and colon cancers
  • genitourinary cancer, such as testis, bladder and prostate cancers
  • hematologic disorders, including multiple myeloma and leukemia
  • thoracic cancer
  • thymoma and thymic carcinoma
  • tumors associated with neurofibromatosis type 1, primarily in children
  • umbilical stem cell transplantation

Each year, the center offers hundreds of adult and pediatric clinical trials. Because of the reach of the Hoosier Cancer Research Network – the community outreach arm of the center – Hoosiers don’t have to travel to Indianapolis for access to the latest trials. Instead, patients across the state are within 60 miles of a clinical research site. A model for community-academic partnerships, the Hoosier Cancer Research Network offers ease of access to clinical studies for patients in rural parts of the state so they can receive treatments close to home.

The IU Simon Comprehensive Cancer Center also is a member of the Big Ten Cancer Research Consortium, a network of academic institutions working together on highly translational clinical trials using the expertise of Big Ten universities.

Website: www.cancer.iu.edu
Contact: (317) 278-5632; iutrials@iu.edu

Trials at this location:

HCRN BRE18-334

A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)

Status: Open to Accrual
Read More

HCRN ESO17-325

A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Status: Open to Accrual
Read More

HCRN GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Status: Open to Accrual
Read More

HCRN LUN18-335

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Status: Open to Accrual
Read More

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Status: Open to Accrual
Read More

HCRN BRE12-158

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.

Status: Closed to Accrual
Read More

HCRN GI14-198

Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients

Status: Closed to Accrual
Read More

HCRN GI15-225

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225

Status: Closed to Accrual
Read More

HCRN GU14-182

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182

Status: Closed to Accrual
Read More

HCRN GU14-188

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

Status: Closed to Accrual
Read More

HCRN GU17-289

A Phase II Randomized, Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289)

Status: Closed to Accrual
Read More

HCRN GU17-295

A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

Status: Closed to Accrual
Read More

HCRN GU17-326

A Phase II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination with Nivolumab plus Ipilimumab in Patients with Renal Cell Carcinoma Previously Treated with Nivolumab plus Ipilimumab

Status: Closed to Accrual
Read More

HCRN LUN14-179

A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab (MK-3475) for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179

Status: Closed to Accrual
Read More

HCRN LUN17-321

A Phase II Study of Concurrent Chemoradiation Plus Durvalumab (MEDI4736) Followed by Surgery Followed by Adjuvant Durvalumab (MEDI4736) in Medically Operable Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Status: Closed to Accrual
Read More

TBCRC029

Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.

Status: Closed to Accrual
Read More

TBCRC035

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)

Status: Closed to Accrual
Read More